Abstract
Introduction:
Mayaro Fever (MF) is a tropical disease caused by the Mayaro virus (MAYV), with outbreaks documented in Latin America.
Methods:
A hospital-based fever surveillance in Leticia, Colombian Amazon, collected sera from 1,460 patients aged 5-89 between December 2020 and April 2023.
Results:
Dengue and malaria were the main diagnoses (19.4 and 5.8%, respectively), leaving 71.4% of cases unidentified after testing. Metagenomic sequencing and real-time RT-qPCR testing identified MAYV in two patients (25-year-old male and an 80-year-old female) exhibiting typical symptoms, of MF including rash, joint pain, and fever. Phylogenetics analysis of these two viruses revealed a close relationship to Peruvian strains within the MAYV D genotype.
Discussion:
The study of AFI in Leticia, Colombia, identified dengue as prevalent, with malaria, COVID-19, Influenza, and Zika viruses also detected. Despite extensive testing, most cases remained unexplained until metagenomic sequencing revealed MAYV, previously unseen in Colombia but known in neighboring countries.
Conclusion:
This study presents the first near full-length genomes of MAYV in Colombia, highlighting the need for further seroprevalence studies and enhanced surveillance to understand and control the spread of the virus in the region.
Introduction
Mayaro Virus (MAYV) is an arthropod-borne, single-stranded RNA virus that belongs to the Semliki Forest antigenic sero-complex, a serological group within the alphavirus genus (family Togaviridae) (). MAYV was initially identified in the Mayaro county, Trinidad in 1954 and since then, several cases of Mayaro fever (MF) have been reported in Latin America and the Caribbean (). Four distinct MAYV genotypes have been recently identified in South America (). MAYV infections pose a significant health concern in Latin America, particularly in regions like South America, where the virus is endemic. Brazil, Peru, and Venezuela have documented the highest incidence and prevalence of Mayaro fever (). Despite being relatively understudied compared to other mosquito-borne viruses like dengue and Zika, MAYV has been identified as a cause of Acute Febrile Illness (AFI) in the region. While cases vary due to underreporting and limited surveillance, sporadic outbreaks and localized transmission have been documented, particularly in areas with favorable ecological conditions for the virus and its mosquito vectors (). The impact of MAYV infections extends beyond the immediate health effects, often affecting vulnerable populations and burdening healthcare systems already strained by other infectious diseases. Understanding the epidemiology and impact of MAYV infections is crucial for effective public health responses and mitigating the spread of the virus in Latin America.
Acute Febrile Illness (AFI) represents a significant health challenge in tropical regions, where many infectious pathogens circulate, often leading to similar clinical presentations. Clinical manifestations may include arthralgia/arthritis, a maculopapular rash, and other symptoms such as headache, myalgia, retro-orbital pain, vomiting, and diarrhea (). Diagnosing MF can be difficult because its signs and symptoms can be easily confused with other co-occurring infections such as malaria and arboviral diseases such as dengue, chikungunya, and Zika (). Consequently, confirmatory laboratory testing is required (). However, it is very limited in most of the tropical areas. Despite extensive laboratory screening, many AFI cases remain without a specific etiology identified. This diagnostic gap hampers individual patient management and impedes effective public health responses to emerging infectious threats (). Metagenomic next-generation sequencing (mNGS), a powerful molecular technique capable of detecting a broad range of pathogens directly from clinical samples, offers a promising solution to this diagnostic dilemma (). Metagenomic sequencing can unveil the presence of known and novel pathogens by analyzing the entire genetic content within a sample, providing crucial insights into disease causation and facilitating targeted interventions for diagnosed and undiagnosed AFI cases in tropical regions. Several studies on AFI in Colombia have observed a great proportion of febrile cases that remained with unknown diagnoses after routine testing or disease investigation. Therefore, this study aimed to employ mNGS as a diagnostic tool to identify the causative agents of AFI in different regions of Colombia where traditional laboratory methods often fail to provide etiological diagnoses. Through comprehensive genomic analysis of clinical samples, we aimed to elucidate the spectrum of pathogens contributing to AFI, including known and novel infectious agents. By characterizing the microbial diversity in these samples, our goal was to enhance our understanding of AFI epidemiology, inform clinical management strategies, and contribute to developing targeted interventions for improved public health outcomes in tropical settings such as Colombia.
Materials and methods
Study setting
Repository samples used in this study were obtained from a cross-sectional hospital-based fever surveillance program (HFSP) conducted since December 2020 in four different regions of Colombia (Villavicencio, Apartado, Acacias, and Leticia; Figure 2A). This program is part of an ongoing Virus Discovery Research Plan of the Abbott Pandemic Defense Coalition () aimed at understanding infectious causes causing AFI of unknown origin. This study was reviewed and approved by the Ethics Committee of Corporacion Investigaciones Biologicas (CIB 10102022). Written informed consent was secured from adults (18 years or older). Informed assent was obtained from minors (<18 years), and written consent was obtained from their parents or guardians on their behalf. At the enrollment, participants agreed to use their data and left-over specimens for future studies. For the purpose of this study, acute-phase sera collected (from December 2020 to April 2023) from 1,460 febrile individuals (aged 5–89 years) from the municipality of Leticia (located in the Amazon region of Colombia) were used.
FIGURE 1
FIGURE 2
AFI case definition
For this study, AFI was defined as recent onset of fever (body temperature ≥ 38°C at the time of consultation or self-reported history of fever within the preceding seven days) without an obvious focus of infection. AFI was associated with non-specific symptoms such as headache, body rash, and muscle and joint pains ().
Laboratory testing
Samples were initially tested for dengue, malaria at the point-of-care using rapid diagnostic tests (SD Bioline Dengue Duo and Bioline Malaria Ag P.f/Pan, Abbott, IL, USA). Serum and whole blood samples were aliquoted and stored at −80°C until processing at the central lab (One Health Genomic Lab, Universidad Nacional de Colombia, Medellin). Samples were tested by molecular assays (reverse transcription RT-PCR and/or PCR) to detect Malaria, Dengue (DENV), Zika (ZIKV), Chikungunya (CHIKV), Influenza (IV), and Severe-Acute-Respiratory-Syndrome-related Coronavirus (SARS-CoV-2), following protocols described elsewhere (; ; ; ). All samples with unknown etiology were kept at −80°C for further testing.
Virus discovery and sequencing
After laboratory testing, a subset (n = 37) of the repository specimens with unknown etiology was non-randomly selected based on the reported clinical manifestations such as vomit, abdominal pain, skin rash, hemorrhages, and/or diarrhea. Selected samples were subjected to Metagenomic Next Generation Sequencing (mNGS). mNGS was conducted using a NextSeq2000 (Illumina, California, USA) following a protocol described elsewhere (). Contamination was identified when pathogens detected by mNGS did not align with the clinical diagnosis, had not been clinically confirmed, and were not regarded as the cause of the clinical disease. Sequencing data were analyzed using an open-source cloud-based metagenomics platform (; ) using the following filters: category (viruses and viroids), subcategory (Viruses – Phage), threshold (NT rPM > = 10; NR rPM > = 5; NR L (alignment length in bp) > = 50), and pathogen tag (known_pathogens).
Bioinformatics and phylogeographic analysis
Sequence alignment was performed on the MAYV sequences from this study using Samtools v1.15 and BWA v0.7.17 (; ). Complete genome sequences of MAYV were downloaded from the public database GenBank (National Center for Biotechnology Information) and compared to the sequences from this work using MAFFT v7.520 (). A Bayesian phylogeographic analysis was performed (Figure 2) on the MAYV sequences obtained as described previously ().
Results
From December 2020 to April 2023, acute-phase sera were collected from 1,460 febrile individuals (aged 5–89 years, and 57.7% were female) from the municipality of Leticia, located in the Amazon region of Colombia. A total of 19.4% (284/1460) patients were confirmed as dengue after laboratory testing, while 5.8% (85/1460) were diagnosed as malaria, 2.9% (43/1460) as COVID-19, 0.3% (4/1460) as Influenza, and 0.1% (1/1460) as Zika, respectively (Table 1). However, 71.4% (1043 out of 1460) of these AFI cases remained unexplained (Figure 1). To address this, 37 samples were non-randomly selected for mNGS (Figure 1). Most confirmed dengue cases occurred in individuals aged 11–35 years, with peak incidences occurring during the rainy season (second and third trimester). Malaria cases were predominantly found in males aged above 35 years, with peak incidences occurring during July and September. COVID-19 cases were predominantly found in females aged 26–35 years, with incidences occurring throughout the period of study. Influenza cases were widely distributed among age groups and throughout the study period.
TABLE 1
| Diagnostic test | Results (%) | Reference method |
| DENV RT-PCR | 284/1460 (19.4) | |
| DENV Duo RDT | 263/1460 (18.0) | Bioline Dengue Duo (Dengue NS1 Ag + IgG/IgM), Abbott, Illinois, USA |
| 309/1460 (21.2) | ||
| 973/1460 (66.6) | ||
| Malaria PCR | 85/1460 (5.8) | |
| Malaria RDT | 83/1460 (5.7) | SD Bioline Malaria Ag P.f/Pan, Abbott, Illinois, USA |
| SARS-CoV-2 RT-PCR | 43/1460 (2.9) | |
| Influenza RT-PCR | 4/1460 (0.3) | |
| ZIKA RT-PCR | 1/1460 (0.1) | |
| MAYV RT-PCR | 1/80 (1.25) | |
| Negative to all laboratory tests | 1043/1460 (71.4) |
Diagnostics test results on serum samples from febrile patients in Leticia, Colombia.
RT-PCR, reverse transcription polymerase chain reaction; RDT, rapid diagnostic testing.
Results from mNGS revealed that a near full-length (94%) genome of MAYV was detected in one specimen (Figure 2B). This MAYV infection was referred to as the index case, occurring on April 2023 in a 25-year-old male (Let-1430) of Indigenous ethnicity. The subject reported fever, rash, joint pain, retro-orbital pain, shaking chills, abdominal pain, weakness, myalgia, headache, vomiting, and diarrhea. The subject did not report recent travel to areas outside of the vicinity. Additional serum specimens of unknown etiology (n = 80) from Leticia were tested for MAYV infection by real-time RT-qPCR, targeting the untranslated region of the nonstructural protein 1 gene of MAYV. The RT-qPCR method was conducted following a protocol described elsewhere (). Serum samples were selected within a month before and after the index case was identified, and from these, another MAYV infection case was detected. This case occurred in an 80-year-old woman of mixed race (Let-1429) who reported the same symptoms as the index case except for the rash. Metagenomic NGS was also conducted in this specimen, identifying reads for MAYV with high identity (>95%) to the reference genome NC_003417. MAYV isolates were successfully obtained from both cases after inoculating infected serum samples onto sub-confluent Vero cells, following a protocol described elsewhere (). Virus isolation was confirmed by RT-qPCR (Figure 2A).
After mNGS, phylogenetic analysis revealed that MAYV from this study clustered together with genotype D sequences reported from Peru. In addition, phylogeographic analysis using available MAYV genomes revealed that MAYV strains in Colombia may have been introduced from Peru through two independent events (Figure 3) and, therefore, have not originated from a single outbreak. Two full-length genomes of MAYV analyzed in this work were deposited in the GenBank under accession numbers PP505831 and PP505832. Genomic sequencing data analysis for other samples revealed Pegivirus C (n = 1), Prevotella melaninogenica (n = 11), Aeromona caviae (n = 9), Mycobacteroides chelonae (n = 6), Haemophilus influenzae (n = 3), Staphylococcus lugdunensis (n = 2), Mycobacterium avium (n = 2), Klebsiella aerogenes (n = 1), Bordetella bronchiseptica (n = 1) as the most common atypical pathogens identified by mNGS.
FIGURE 3
Discussion
After investigating the landscape of AFI among a cohort of 1,460 individuals in the municipality of Leticia, situated within the Amazon region of Colombia, and primarily focusing on the identification and characterization of pathogens causing such illness, we found that a multifaceted picture emerged with the highest number of cases confirmed of dengue and smaller occurrences of malaria, COVID-19, Influenza and Zika. However, most (71.4%) of AFI cases remained unexplained. MNGS and other laboratory techniques were employed within this enigmatic pool, leading to the pivotal discovery and characterization of MAYV. To our knowledge, while MAYV is recognized as a source of AFI in South America, there have been no documented cases of MAYV infections in Colombia to date.
In agreement with our findings, genotype D of MAYV has been the most reported circulating genotype in South America (). Furthermore, there is strong evidence that MAYV is the cause of AFI outbreaks in neighboring countries, central and South America (; ). A recent report from Peru showed that MAYV infections occurred in 17.3% of 496 febrile cases studied, of which 10.9% were MAYV mono-infections and 6.4% were co-infections with DENV (). Similarly, another study in the same country confirmed MAYV infection by RT-PCR and sequencing in 11.1% (40/359) of the febrile patients tested (). Confirmation of MAYV infections has recently been reported in mosquitoes and humans in Brazil (; ). Natural MAYV infection has also been documented in Culicidae mosquito species in several South American countries, including Colombia (), but additional evidence supporting their involvement in the MAYV transmission in Colombia is required.
There is some evidence of natural infection of MAYV in vector mosquitoes (Psorophora albipes) in the northeast region of Colombia (). However, to our knowledge, MAYV infection in humans has not been previously reported in this country. In addition, detection of MAYV infection may also be challenging when using only molecular testing. The relatively short (approximately 3–10 days) viremia could limit MAYV detection (). Therefore, further seroprevalence studies are highly recommended to comprehensively assess the burden of this disease in the Amazon River basin and Colombia. A recent review of population-based studies reported a seroprevalence of MAYV infection ranging between 6 and 67% for South American countries (), and recently, a seroprevalence study in Mexico showed that MAYV infection occurred in 1% of adults who reported having suffered from an arboviral illness at some point in their lives (). Consequently, our findings indicate that MAYV infections may be cryptically occurring in some regions of Colombia, and cases are being misdiagnosed, thus highlighting the need for active surveillance of MAYV in Colombia.
Atypical viral pathogens such as Pegivirus C and bacteria such as Klebsiella pneumoniae and non-tuberculous mycobacteria have been reported in febrile and patients with respiratory illness after metagenomic sequencing analysis (; ; ; ; ). However, further research is needed to assess its implications in disease pathogenesis, specifically in disease cases of AFI of unknown origin.
Our results contribute to the understanding of MAYV in the Americas and emphasize the importance of implementing metagenomic NGS to detect pathogens causing AFI of unknown origin, especially when other specific detection methods, such as PCR, are not available routinely used for diagnosis. There is also a need to develop commercially available diagnostic tests for MAYV to understand the disease burden better. Finally, we strongly suggest increasing educational campaigns about MAYV for the community, especially for healthcare personnel in high-risk areas of Colombia. Such targeted strategies are pivotal to ensure that communities are aware of this disease and that healthcare professionals in the region are provided with the most recent knowledge to proficiently detect, manage, and address these MAYV infections.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found here: https://www.ncbi.nlm.nih.gov/genbank/, PP505831, https://www.ncbi.nlm.nih.gov/genbank/, PP505832.
Ethics statement
The studies involving humans were approved by the Ethics Committee of Corporación de Investigaciones Biológicas. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
Author contributions
LP-R: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review and editing. KC: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review and editing. JU: Data curation, Methodology, Writing – review and editing. IM: Methodology, Writing – review and editing. VV: Methodology, Writing – review and editing. AA-A: Methodology, Writing – review and editing. MB: Formal analysis, Resources, Writing – review and editing. GC: Funding acquisition, Supervision, Writing – review and editing. JH-O: Writing – review and editing. JO: Funding acquisition, Supervision, Writing – review and editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the University of Wisconsin-Madison GHI One Health Colombia, the Universidad Nacional de Colombia (Medellin), and the Abbott Pandemic Defense Coalition. Thanks to Fundacion Sofia Perez de Soto and Fundacion Fraternidad Medellin for supporting postgraduate students involved in this work.
Acknowledgments
We thank the healthcare institutions’ collaborating staff (Hospital San Rafael de Leticia y Fundación Clínica de Leticia) for their assistance and coordination of fieldwork activities in this study. We also thank the One Health Genomic Laboratory staff at the Universidad Nacional for their assistance during laboratory work.
Conflict of interest
GC and MB are Abbott employees and shareholders. JO is a single owner of Vaccigen, LLC. JO and JH-O are employees and shareholders of VaxThera. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Acosta-AmpudiaY.MonsalveD.RodríguezY.PachecoY.AnayaJ.Ramírez-SantanaC.et al (2018). Mayaro: an emerging viral threat?Emerg. Microbes Infect.7:163.
2
Aguilar-LuisM. A.Del Valle-MendozaJ.SandovalI.Silva-CasoW.MazulisF.Carrillo-NgH.et al (2021). A silent public health threat: emergence of Mayaro virus and co-infection with Dengue in Peru.BMC Res. Notes14:29. 10.1186/s13104-021-05444-8
3
Aguilar-LuisM. A.Valle-MendozaJ.SandovalI.Silva-CasoW.MazulisF.Carrillo-NgH.et al (2020). An emerging public health threat: Mayaro virus increases its distribution in Peru.Int. J. Infect. Dis.92253–258. 10.1016/j.ijid.2020.01.024
4
ArroyaveE.LondonoA. F.QuinteroJ. C.Agudelo-FlorezP.ArboledaM.DiazF. J.et al (2013). Etiología y caracterización epidemiológica del síndrome febril no palúdico en tres municipios del Urabá antioqueño, Colombia.Biomedica3399–107.
5
AverhoffF.BergM.RodgersM.OsmanovS.LuoX.AndersonM.et al (2022). The abbott pandemic defense coalition: a unique multisector approach adds to global pandemic preparedness efforts.Int. J. Infect. Dis.117356–360. 10.1016/j.ijid.2022.02.001
6
BarathanM. (2024). From fever to action: diagnosis, treatment, and prevention of acute undifferentiated febrile illnesses.Pathog. Dis.82:ftae006.
7
BatoolM.Galloway-PeñaJ. (2023). Clinical metagenomics—challenges and future prospects.Front. Microbiol.14:1186424. 10.3389/fmicb.2023.1186424
8
BergM. G.OlivoA.ForbergK.HarrisB.YamaguchiJ.ShiraziR.et al (2020). Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses.PLoS One15:e0236046. 10.1371/journal.pone.0236046
9
BlohmG. M.Márquez-ColmenarezM. C.LednickyJ. A.BonnyT. S.MavianC.SalemiM.et al (2019). Isolation of Mayaro virus from a Venezuelan patient with febrile illness, arthralgias, and rash: further evidence of regional strain circulation and possible long-term endemicity.Am. J. Trop. Med. Hyg.1011219–1225. 10.4269/ajtmh.19-0357
10
CaicedoE.-Y.CharnigaK.RuedaA.DorigattiI.MendezY.HamletA.et al (2023). Correction: the epidemiology of Mayaro virus in the Americas: a systematic review and key parameter estimates for outbreak modelling.PLoS Negl. Trop. Dis.17:e0011034. 10.1371/journal.pntd.0011034
11
CeloneM.PotterA.HanB.BeemanS.OkechB.ForsheyB.et al (2023). A geopositioned and evidence-graded pan-species compendium of Mayaro virus occurrence.Sci. Data10:460. 10.1038/s41597-023-02302-z
12
CiuoderisK. A.UsugaJ.MorenoI.Perez-RestrepoL.FlórezD.CardonaA.et al (2023). Characterization of Dengue virus Serotype 2 cosmopolitan genotype circulating in Colombia.Am. J. Trop. Med. Hyg.1091298–1302. 10.4269/ajtmh.23-0375
13
CormanV. M.LandtO.KaiserM.MolenkampR.MeijerA.ChuK. W.et al (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.Eurosurveillance25:2000045.
14
de CurcioJ. S.Salem-IzaccS.Pereira NetoL.NunesE.AnunciaçãoC.Silveira-LacerdaE.et al (2022). Detection of Mayaro virus in Aedes aegypti mosquitoes circulating in Goiânia-Goiás-Brazil.Microbes Infect.24:104948. 10.1016/j.micinf.2022.104948
15
Del Carpio-OrantesL.Mejía-RamosS. G.Aguilar-SilvaA. (2022). Seroprevalence of Mayaro virus infection in Veracruz, Mexico.Travel Med. Infect. Dis.50:102464.
16
del Valle-MendozaJ.Silva-CasoW.Cornejo-TapiaA.Orellana-PeraltaF.VerneE.UgarteC.et al (2017). Molecular etiological profile of atypical bacterial pathogens, viruses and coinfections among infants and children with community acquired pneumonia admitted to a national hospital in Lima.Peru. BMC Res. Notes10:688. 10.1186/s13104-017-3000-3
17
de-ParisF.BeckC.MachadoA.PaivaR.da Silva MenezesD. (2012). Optimization of one-step duplex real-time RT-PCR for detection of influenza and respiratory syncytial virus in nasopharyngeal aspirates.J. Virol. Methods186189–192. 10.1016/j.jviromet.2012.07.008
18
DiagneC. T.BengueM.ChoumetV.HamelR.PomponJ. (2020). Mayaro virus pathogenesis and transmission mechanisms.Pathogens9:738.
19
KalantarK. L.CarvalhoT.de BourcyC.DimitrovB.DingleG.EggerR.et al (2020). IDseq-An open source cloud-based pipeline and analysis service for metagenomic pathogen detection and monitoring.Gigascience9:giaa111. 10.1093/gigascience/giaa111
20
KamauE.AlemayehuS.FeghaliK. C.SaundersD.OckenhouseC. F. (2013). Multiplex qPCR for detection and absolute quantification of Malaria.PLoS One8:e71539. 10.1371/journal.pone.0071539
21
KatohK.RozewickiJ.YamadaK. D. (2019). MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization.Brief. Bioinform.201160–1166. 10.1093/bib/bbx108
22
LiH.DurbinR. (2009). Fast and accurate short read alignment with Burrows–Wheeler transform.Bioinformatics251754–1760.
23
LiH.HandsakerB.WysokerA.FennellT.RuanJ.HomerN.et al (2009). The sequence alignment/map format and SAMtools.Bioinformatics252078–2079.
24
LorenzC.Freitas RibeiroA.Chiaravalloti-NetoF. (2019). Mayaro virus distribution in South America.Acta Trop.198:105093.
25
MavianC.RifeB.DollarJ.CellaE.CiccozziM.ProsperiM.et al (2017). Emergence of recombinant Mayaro virus strains from the Amazon basin.Sci. Rep.7:8718. 10.1038/s41598-017-07152-5
26
OguzieJ. U.PetrosB.OluniyiP.MehtaS.EromonP.NairP.et al (2023). Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria.Nat. Commun.14:4693. 10.1038/s41467-023-40247-4
27
PezziL.ReuskenC.WeaverS.DrexlerJ.BuschM.LaBeaudA.et al (2019). GloPID-R report on Chikungunya, O’nyong-nyong and Mayaro virus, part I: biological diagnostics.Antiviral Res.16666–81.
28
SaatkampC. J.RodriguesL.PereiraA.CoelhoJ.MarquesR.SouzaV.et al (2021). Mayaro virus detection in the western region of Pará state, Brazil.Rev. Soc. Bras. Med. Trop.54e0055–e2020. 10.1590/0037-8682-0055-2020
29
ShenH.LiuT.ShenM.ZhangY.ChenW.ChenH.et al (2023). Utilizing metagenomic next-generation sequencing for diagnosis and lung microbiome probing of pediatric pneumonia through bronchoalveolar lavage fluid in pediatric intensive care unit: results from a large real-world cohort.Front. Cell. Infect. Microbiol.13:1200806. 10.3389/fcimb.2023.1200806
30
TunZ. M.MoorthyM.LinsterM.SuY.CokerR.OoiE.et al (2016). Characteristics of acute febrile illness and determinants of illness recovery among adults presenting to Singapore primary care clinics.BMC Infect. Dis.16:612. 10.1186/s12879-016-1958-4
31
WaggonerJ. J.GreshL.Mohamed-HadleyA.BallesterosG.DavilaM.TellezY.et al (2016). Single-reaction multiplex reverse transcription PCR for detection of Zika, Chikungunya, and Dengue Viruses.Emerg. Infect. Dis.221295–1297.
32
WaggonerJ. J.RojasA.Mohamed-HadleyA.de GuillénY. A.PinskyB. A. (2018). Real-time RT-PCR for Mayaro virus detection in plasma and urine.J. Clin. Virol.981–4. 10.1016/j.jcv.2017.11.006
33
WeiY.ZhangT.MaY.YanJ.ZhanJ.ZhengJ.et al (2023). Clinical evaluation of Metagenomic next-generation sequencing for the detection of pathogens in BALF in severe community acquired pneumonia.Ital. J. Pediatr.49:25.
34
YangH.XuN.YanM.YangL.WenS.WangS.et al (2024). Comparison of metagenomic next-generation sequencing and conventional culture for the diagnostic performance in febrile patients with suspected infections.BMC Infect. Dis.24:350. 10.1186/s12879-024-09236-w
Summary
Keywords
Mayaro Virus, Acute Febrile Illness, whole genome sequencing, Colombia, fever
Citation
Perez-Restrepo LS, Ciuoderis K, Usuga J, Moreno I, Vargas V, Arévalo-Arbelaez AJ, Berg MG, Cloherty GA, Hernández-Ortiz JP and Osorio JE (2024) Mayaro Virus as the cause of Acute Febrile Illness in the Colombian Amazon Basin. Front. Microbiol. 15:1419637. doi: 10.3389/fmicb.2024.1419637
Received
18 April 2024
Accepted
25 June 2024
Published
09 July 2024
Volume
15 - 2024
Edited by
Ke Liu, Chinese Academy of Agricultural Sciences, China
Reviewed by
Sandra Junglen, Charité Medical University of Berlin, Germany
Robert Andreata-Santos, Federal University of São Paulo, Brazil
Updates
Copyright
© 2024 Perez-Restrepo, Ciuoderis, Usuga, Moreno, Vargas, Arévalo-Arbelaez, Berg, Cloherty, Hernández-Ortiz and Osorio.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Juan Pablo Hernández-Ortiz, jphernandezo@unal.edu.co
†These authors have contributed equally to this work and shared first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.